KLRK1 and prostate cancer: Likewise, Lundholm et al. [126] found that ExVs secreted by prostate cancer cells expressed ligands for NKG2D on their surface and selectively downregulated NKG2D on NK and CD8+T cells, in a dose-dependent manner, leading to impaired cytotoxic function in vitro.